Breaking
πŸ‡ͺπŸ‡Ί EMA
Whitepaper EU Score 85/100

Overview of Comments Received on ICH Q3E Guideline

This document summarizes comments on the ICH Q3E Guideline regarding extractables and leachables, focusing on regulatory and safety considerations.

Publisher
European Medicines Agency
Published
Length
192 pages
File
1.6 MB PDF
Overview of Comments Received on ICH Q3E Guideline β€” cover
⬇

Download the full 192-page PDF

Free Β· 1.6 MB Β· Instant access after email

πŸ”’ We never share your email. Single-click download.

# Executive Summary This whitepaper provides an overview of comments received on the ICH Q3E Guideline concerning extractables and leachables (E&L). Key findings include: - **Regulatory Insights**: Comments highlight the need for clarity on the application of E&L testing across various product types. - **Methodological Recommendations**: Suggestions for improving methodologies for assessing leachables and extractables in drug packaging. - **Terminology Consistency**: Calls for harmonization of terminology related to E&L to avoid confusion in regulatory contexts. - **Safety Assessments**: Emphasis on the importance of safety assessments for pediatric products and other vulnerable populations. - **Risk Assessment Protocols**: Recommendations for implementing risk-based approaches to determine the necessity of E&L testing.

Ready to read the full report?

Join 12,000+ pharma leaders getting deep industry analysis delivered weekly.

Download PDF ↓